Gender Differences in Psychopharmacology

Principles of Gender-Specific Medicine

Volumn 1, Issue , 2004, Pages 145-154

  Chue, Pierre ^a  

^a UNIVERSITY OF ALBERTA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84902055676     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-012440905-7/50281-4     Document Type: Chapter

References (193)

1. Roe CM, McNamara AM, Motheral B Gender-and age-related prescription drug use patterns. Ann Pharmacotherapy 2002, 36:30-35.
2. Ott BR, Lapane KL, Gambassi G Gender differences in the treatment of behaviour problems in Alzheimer's disease. Neurology 2000, 54:427-432.
3. Cohen LS, Dickson RA Sex-based differences in antipsychotic therapy. A Monograph for Continuing Medical Education Credit 1997, 1-16. Pragmaton, Chicago, Illinois.
4. Baum C, Kennedy DL, Knapp DE, et al. Prescription drug use in 1984 and changes over time. Med Care 1988, 26:105-114.
5. Fankhauser MP Psychiatric disorders in women: Psychopharmacologic treatments. J Am Pharmaceut Assoc 1997, 37:667-678.
6. Kando JC, Yonkers KA, Cole JO Gender as a risk factor for adverse events to medications. Drugs 1995, 50:1-6.
7. Domecq C, Naranjo CA, Ruiz I, et al. Sex-related variations in the frequency and characteristics of adverse drug reactions. Int J Clin Pharmacol Ther Toxicol 1980, 18:362-366.
8. Robinson GE Women and psychopharmacology. Medscape Women's Health eJournal 2002, 7:1-8.
9. Pollock BG Gender differences in psychotropic drug metabolism. Psychopharmacol Bull 1997, 33:235-241.
10. Harris RZ, Benet LZ, Schwartz JB Gender effects in pharmacokinetics and pharmacodynamics. Drugs 1995, 50:222-239.
11. Hamilton JA, Yonkers KA Sex differences in pharmacokinetics of psychotropic medications, part I: Physiological basis for effects. Psychopharmacology and Women: Sex, Gender, and Hormones 1996, 11-42. American Psychiatric Press, Washington, DC. M.F. Jensvold, U. Halbreich, J.A. Hamilton (Eds.).
12. Brawman-Mintzer O, Yonkers KA Psychopharmacology in women. Psychological Aspects of Women's Health Care: The Interface Between Psychiatry and Obstetrics and Gynaecology 2001, 401-420. American Psychiatric Press, Washington, DC. 2nd Edition. N.L. Stotland, D.E. Stewart (Eds.).
13. Yonkers KA, Kando JC, Cole JO, et al. Gender differences in pharmacokinetics and pharmacodynamics in psychotropic medication. Am J Psychiatry 1992, 149:587-595.
14. Dawkins K, Potter WZ Gender differences in pharmacokinetics and pharmacodynamics of psychotropics: Focus on women. Psychopharmacol Bull 1991, 27:417-426.
15. Ochs HR, Greenblatt DJ, Divoll M, et al. Diazepam kinetics in relation to age and sex. Pharmacology 1989, 232:183-188.
16. Greenblatt DJ, Allen MD, Harmatz JS, et al. Diazepam disposition determinants. Clin Pharmacol Ther 1980, 27:301-312.
17. Greenblatt DJ, Allen MD, Harmatz JS, et al. Oxazepam kinetics: Effects of age and sex. J Pharmacol Exp Ther 1980, 215:86-91.
18. Allen MD, Greenblatt DJ, Harmatz JS, et al. Desmethyldiazepam kinetics in the elderly after oral prazepam. Clin Pharmacol Ther 1980, 28:196-202.
19. Divoll M, Greenblatt DJ, Harmatz JS, Shader RI Effects of age and gender on disposition of temazepam. J Pharm Sci 1981, 70:1104-1107.
20. Greenblatt DJ, Divoll MK, Shader RI Age and gender effects on chlordiazepoxide kinetics: Relation to antipyrine disposition. Pharmacology 1989, 38:327-334.
21. Jochemsen R, Van der Graaffs M, Boejinga JK, et al. Influence of sex, menstrual cycle and oral contraceptives on the disposal of nitrazepam. Br J Clin Pharmacol 1982, 13:319-324.
22. Ochs HR, Greenblatt DJ, Friedman, et al. Bromazepam pharmacokinetics: Influence of age, gender, oral contraceptives, cimetidine, and propanolol. Clin Pharmacol 1987, 41:562-567.
23. Divoll M, Greenblatt DJ Effect of age and sex on lorazepam protein binding. J Pharm Pharmacol 1982, 34:122-123.
24. Smith RB, Divoll M, Gillespie WR, et al. Effect of subject age and gender on the pharmacokinetics of oral triazolam and temazepam. J Clin Psychopharmacol 1983, 3:171-176.
25. Kristjansson F, Thorsteinsson SB Disposition of alprazolam in human volunteers: Differences between genders. Acta Pharm Nord 1991, 3:249-250.
26. Greenblatt DJ, Divoll M, Abernethy DR, et al. Alprazolam kinetics in the elderly. Arch Gen Psychiatry 1983, 40:287-290.
27. Datz FL, Christian PE, Moore JG Gender-related differences in gastric emptying. J Nucl Med 1987, 28:1204-1207.
28. Hutson WR, Roehrkasse RL, Wald A Influence of gender and menopause on gastric emptying and motility. Gastroenterology 1989, 96:11-17.
29. Yamagata S, Ishimori A, Sato H, et al. Secretory function of the stomach of Japanese with endoscopically normal gastric mucosa. Gastroenterol Japan 1975, 10:162-167.
30. Frezza M, di Padova C, Pozzato G, et al. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first pass metabolism. N Engl J Med 1990, 322:95-99.
31. Gaudry SE, Sitar DS, Smyth DD, et al. Gender and age as factors in the inhibition of renal clearance of amantadine by quinine and quinidine. Clin Pharmacol Ther 1993, 54:23-27.
32. Lusseveld EM, Peters ET, Deurenberg P Multifrequency bioelectrical impedance as a measure of differences in body water distribution. Ann Nutr Metab 1993, 37:44-51.
33. Seeman MV Prescribing neuroleptics for men and women. J Soc Pharmacol 1989, 3:219-236.
34. Gur RC, Gur RE, Obrist WD, et al. Sex and handedness differences in cerebral blood flow during rest and cognitive activity. Science 1982, 217:659-661.
35. Wilson K Sex-related differences in drug disposition in man. Clin Pharmacokinet 1984, 9:189-202.
36. Gex-Fabry M, Balant-Gorgia AE, Balant LP, Garone G Clomipramine metabolism. Model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 1990, 19:241-255.
37. Mundo E, Pirola R, Bellodi L, et al. Are gender differences in anti-obsessional response related to different clomipramine metabolism?. J Clin Psychopharmacol 2002, 22:341-342.
38. Smith M, Lin K-M Gender and ethnic differences in the pharmacogenetics of psychotropics. Psychopharmacology and Women: Sex, Gender, and Hormones 1996, 121-136. American Psychiatric Press Inc., Washington, DC. M.F. Jensvold, U. Halbreich, J.A. Hamilton (Eds.).
39. Wadelius M, Darj E, Frenne G, Rane A Induction of CYP2D6 in pregnancy. Clin Pharmacol Ther 1997, 62:400-407.
40. Pigott TA Gender differences in the epidemiology and treatment of anxiety disorders. J Clin Psychiatry 1999, 60:4-14.
41. Ereshefsky L, Saklad SR, Watanabe MD, et al. Thiothixene pharmacokinetic interactions: A study of hepatic enzyme inducers, clearance inhibitors, and demographic variables. J Clin Psychopharmacol 1991, 11:296-301.
42. Kendall D, Stancel G, Enna S The infleunce of sex hormones on antidepressant-induced alterations in neurotransmitter receptor binding. J Neurosci 1982, 2:354-360.
43. Frackiewicz EJ, Sramek JJ, Cutler NR Gender differences in depression and antidepressant pharmacokinetics and adverse events. Ann Pharmacotherapy 2000, 34:80-88.
44. Davidson J, Pelton S Form of atypical depression and their response to antidepressant drugs. Psychiatry Res 1986, 17:87-95.
45. Raskin A Age-sex differences in response to antidepressant drugs. J Nerv Ment Dis 1974, 159:120-130.
46. Routledge PA, Stargel WW, Kitchell BB, et al. Sex-related differences in the plasma protein binding of lignocaine and diazepam. Br J Clin Pharmacol 1981, 11:245-250.
47. Abel JG, Sellers EM, Naranjo CA, et al. Inter- and intra-subject variation in diazepam free fraction. Clin Pharmacol Ther 1979, 26:247-255.
48. Roberts RK, Desmond PV, Wilkinson GR, et al. Disposition of chlordiazepoxide: Sex differences and effects of oral contraceptives. Clin Pharmacol Ther 1979, 25:826-831.
49. Kristensen C Imipramine serum protein binding in healthy subjects. Clin Pharmacol Ther 1983, 34:689-694.
50. Gill RC, Murphy PD, Hopper HR, et al. Effect of the menstrual cycle on gastric emptying. Digestion 1987, 36:168-174.
51. Petring OU, Flacks H Inter- and intrasubject variability of gastric emptying in healthy volunteers measured by scintigraphy and paracetamol absorption. Br J Clin Pharmacol 1990, 29:703-708.
52. Sakaguchi T, Yamazaki M, Itoh S, et al. Gastric acid secretion controlled by oestrogen in women. J Int Med Res 1991, 19:384-388.
53. Wald A, Van Thiel DH, Hoechstetter L, et al. Gastrointestinal transit: The effect of the menstrual cycle. Gastroenterol 1981, 80:1497-1500.
54. Stewart DE, Fairman M, Barbadoro S, et al. Follicular and late luteal phase serum fluoxetine levels in women suffering from late luteal phase dysphoric disorder. Biol Psychiatry 1994, 36:201-202.
55. Kirkwood C, Moore A, Hayes P, et al. Influence of menstrual cycle and gender on alprazolam pharmacokinetics. Clin Pharmacol Ther 1991, 50:404-409.
56. Backstrom P, Jorpes P Serum phenytoin, phenobarbital, carbamazepine, albumin, and plasma estradiol progesterone concentrations during the menstrual cycle in women with epilepsy. Neurol Scand 1979, 58:63-71.
57. Wilson K, Reynolds CN, Burnett D Inter- and intra-individual variation in the metabolism of methaqualone in man after a single oral dose. Eur J Clin Pharmacol 1978, 13:291-297.
58. Shavit G, Lerman P, Korczyn AD, et al. Phenytoin pharmacokinetics in catamenial epilepsy. Neurology 1984, 34:959-961.
59. Conrad CD, Hamilton JA Recurrent premenstrual decline in serum lithium concentration: Clinical correlates and treatment implications. J Am Acad Child Psychiatry 1986, 26:852-853.
60. Klaiber EL, Broverman DM, Vogel W, et al. Estrogen therapy for severe persistent depression in women. Arch Gen Psychiatry 1979, 36:550-554.
61. Jones BM, Jones MK Alcohol effects in women during the menstrual cycle. Ann NY Acad Sci 1977, 273:576-587.
62. Gleiter CH, Gundert-Remy U Gender differences in pharmacokinetics. Eur J Drug Metab Pharmacokinet 1996, 21:123-128.
63. Wisner KL, Gelenberg AJ, Leonard H, et al. Pharmacologic treatment of depression during pregnancy. JAMA 1999, 282:1264-1269.
64. Bologa M, Tang B, Klein J, et al. Pregnancy-induced changes in drug metabolism in epileptic women. J Pharmacol Exp Ther 1991, 257:735-740.
65. Kilpatric CJ, Moulds RF Anticonvulsants in pregnancy. Epilepsia 1994, 35:131-135.
66. Yerby MS Pregnancy and epilepsy. Epilepsia 1991, 32:S51-S59.
67. Cohen LS, Rosenbaum JF Psychotropic drug use during pregnancy: Weighing the risks. J Clin Psychiatry 1998, 59:18-28.
68. Murray L, Seger D Drug therapy during pregnancy and lactation. Emerg Med Clin North Am 1994, 12:129-149.
69. Stewart DE, Robinson GE Psychotropic drugs and ECT during pregnancy and lactation. Psychological Aspects of Women's Health 2001, 67-93. American Psychiatric Press, Washington, DC. 2nd Edition. N.L. Stotland, D.E. Stewart (Eds.).
70. Pinkofsky HB Effects of antipsychotics on the unborn child. Paediatr Drugs 2000, 2:83-90.
71. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997, 336:258-262.
72. Einarson A, Fatoye B, Sarkar M, et al. Pregnancy outcome following gestational exposure to venlafaxine: A multicenter prospective controlled study. Am J Psychiatry 2001, 158:1728-1730.
73. Jacobson SJ, Jones K, Johnson K, et al. Prospective multicentre study of pregnancy outcome after lithium exposure during first trimester. Lancet 1992, 339:530-533.
74. Altshuler LL, Cohen L, Szuba MP, et al. Pharmacologic management of psychiatric illness during pregnancy: Dilemmas and guidelines. Am J Psychiatry 1996, 153:592-606.
75. Viguera AC, Cohen LS, Baldessarini RJ, Nonacs R Managing bipolar disorder during pregnancy: Weighing the risks and benefits. Can J Psychiatry 2002, 47:426-436.
76. Jones KL, Lacro RV, Johnson KA, et al. Pattern of malformations in the children of women treated with carbamazepine during pregnancy. N Engl J Med 1989, 320:1661-1666.
77. Koren G, Kennedy D Safe use of valproic acid during pregnancy. Can Fam Physician 1999, 45:1451-1453.
78. Dickson RA, Hogg L Pregnancy of a patient treated with clozapine. Psychiatr Serv 1998, 49:997.
79. Stiskal JA, Kulin N, Koren G, et al. Neonatal paroxetine withdrawal syndrome. Arch Dis Child Fetal Neonatal Ed 2001, 85:147-148.
80. Llewellyn A, Stowe ZN Psychotropic medications in lactation. J Clin Psychiatry 1998, 59:41-52.
81. Ananth J Side effects in the neonate from psychotropic agents excreted through breastfeeding. Am J Psychiatry 1978, 135:801-805.
82. Schou M, Amdisen A Lithium and pregnancy: Lithium ingestion by children breastfed by women on lithium treatment. BMJ 1973, 2:137-138.
83. Tunnessen WW, Hertz CG Toxic effects of lithium in newborn infants: A commentary. J Pediatr 1972, 81:804-807.
84. Bar-Oz B, Nulman I, Koren G, et al. Anticonvulsants and breastfeeding. Paediatr Drugs 2000, 2:113-126.
85. Sweet R, Pollock B, Wright, et al. Single and multiple dose bupropion pharmacokinetics in elderly women with depression. J Clin Pharmacol 1995, 35:876-884.
86. Holazo AA, Winkler MB, Patel IH Effects of age, gender and oral contraceptives on intramuscular midazolam pharmacokinetics. J Clin Pharmacol 1988, 28:1040-1045.
87. MacLeod SM, Giles HG, Bengert B, et al. Age and gender-related differences in diazepam pharmacokinetics. J Clin Pharmacol 1979, 19:15-19.
88. Preskorn SH, Mac DS Plasma level of amitriptyline: Effect of age and sex. J Clin Psychiatry 1985, 46:276-277.
89. Barbhaiya RH, Buch AB, Greene DS A study of the effect of age and gender on the pharmacokinetics of nefazodone after single and multiple doses. J Clin Psychopharmacol 1996, 16:19-25.
90. Abernethy DR, Greenblatt DJ, Shader RI Imipramine and desipramine disposition in the elderly. J Pharmacol Exp Ther 1985, 232:183-188.
91. Greenblatt DJ, Friedman H, Burstein ES, et al. Trazodone kinetics: Effect of age, gender, and obesity. Clin Pharmacol Ther 1987, 42:193-200.
92. Ronfeld RA, Tremaine LM, Wilner KD Pharmacokinetics of sertraline and its N-desmethyl metabolite in elderly and young male and female volunteers. Clin Pharmacokinet 1997, 32(Suppl 1):22-30.
93. Wong SL, Cao G, Mack RJ, Granneman GR Pharmacokinetics of sertindole in healthy young and elderly male and female subjects. Clin Pharmacol Ther 1997, 62:157-164.
94. Salokangas RK, Saarijarvi S, Taiminen T, et al. Effect of smoking on neuroleptics in schizophrenia. Schizophr Res 1997, 23:55-60.
95. Abernethy DR, Greenblatt DJ, Shader RI Imipramine disposition in users of oral contraceptive steroids. Clin Pharmacol Ther 1984, 35:792-797.
96. Stoehr GP, Kroboth PD, Juhl RP, et al. Effect of oral contraceptives on triazolam, temazepam, alprazolam, and lorazepam kinetics. Clin Pharmacol Ther. 1984, 36:683-690.
97. Abernethy DR, Greenblatt DJ, Divoll M, et al. Impairment of diazepam metabolism by low dose estrogen-containing oral-contraceptive steroids. N Engl J Med. 1982, 306:791-792.
98. Giles HG, Sellers EM, Naranjo CA, et al. Disposition of intravenous diazepam in young men and women. Eur J Clin Pharmacol. 1981, 20:207-213.
99. Kroboth PD, Smith RB, Stoehr GP, et al. Pharmacodynamic evaluation of the benzodiazepine-oral contraceptive interaction. Clin Pharmacol Ther. 1985, 38:525-532.
100. Ellinwood EH, Easler ME, Linnoila M, et al. Effects of oral contraceptives on diazepam-induced psychomotor impairment. Clin Pharmacol Ther. 1984, 35:360-366.
101. Harris RB, Laws A, Reddy VM, et al. Are women using postmenopausal oestrogens? A community survey. Am J Public Health. 1990, 80:1266-1268.
102. Schneider LS, Small GW, Clary CM Estrogen replacement therapy and antidepressant response to sertraline in older depressed women. Am J Geriatr Psychiatry 2001, 9:393-399.
103. Dahl M, Bertilsson L, Nordin C Steady-state plasma levels of nortriptyline and its 10-hydroxy metabolite: Relationship to the CYP2D6 genotype. Psychopharmacology (Berl) 1996, 123:315-319.
104. Zhang-Wong J, Beiser M, Zipursky RB, Bean G An investigation of ethnic and gender differences in the pharmacodynamics of haloperidol. Psychiatry Res. 1998, 81:333-339.
105. Seeman MV Gender issues in the psychopharmacology of schizophrenia. Current Issues in the Psychopharmacology of Schizophrenia 2001, 487-496. Lippincott Williams and Wilkins, Philadelphia, PA. A. Breier, P.V. Tran (Eds.).
106. Weinstock LS Gender differences in the presentation and management of social anxiety disorder. J Clin Psychiatry 1999, 60:9-13.
107. Kornstein SG, Schatzberg AF, Thase ME, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry 2000, 157:1445-1452.
108. Hamilton JA, Grant M, Jensvold MF Sex and treatment of depression: When does it matter?. Psychopharmacology and Women: Sex, Gender, and Hormones 1996, 241-260. American Psychiatric Press Inc., Washington, DC. M.F. Jensvold, U. Halbreich, J.A. Hamilton (Eds.).
109. Glassman AH, Perel JM, Shostak M, et al. Clinical implications of imipramine plasma levels for depressive illness. Arch Gen Psychiatry 1977, 34:197-204.
110. Rubinow DR, Schmidt PJ, Roca CA Hormonal and gender influences on mood regulation. Neuropsychopharmacology. The Fifth Generation of Progress 2002, 1165-1178. Lippincott Williams and Wilkins, Philadelphia, PA. K.L. Davis, D. Charney, J.T. Coyle, C. Nemeroff (Eds.).
111. Steiner M, Wheadon DE, Kreider MS, et al. Antidepressant response to paroxetine by gender. Presented at the 146th Annual Meeting of the American Psychiatric Association May 22-27, 1993.
112. Martenyi F, Dossenbach M, Mraz K, Metcalfe S Gender differences in the efficacy of fluoxetine and maprotiline in depressed patients: A double blind trial of antidepressants with serotonergic or norepinephric reuptake inhibition profile. Eur Neuropsychopharmacology 2001, 11:227-232.
113. Whybrow PC Sex differences in thyroid axis function: Relevance to affective disorder and its treatment. Depression 1995, 3:33-42.
114. Altshuler LL, Post RM, Leverich GS, et al. Antidepressant-induced mania and cycle acceleration: A controversy revisited. Am J Psychiatry 1995, 152:1130-1138.
115. Mundo E, Bareggi SR, Pirola R, Bellodi L Effect of acute intravenous clomipramine and antiobsessional response to proserotonergic drugs: Is gender a predictive variable. Biological Psychiatry 1999, 45:290-294.
116. Prange AJ Estrogen may well affect response to antidepressant. JAMA 1972, 219:143-144.
117. Moody JP, Tait AC, Todrick A Plasma levels of imipramine and desmethylimipramine during therapy. Br J Psychiatry 1967, 113:183-193.
118. Timmer CJ, Ad Sitsen J-M, Delbressine LP Clinical pharmacokinetics of mirtazapine. Clin Pharmacokinet. 2000, 38:461-474.
119. Hartter S, Wetzel H, Hammes E, et al. Nonlinear pharmacokinetics of fluvoxamine and gender differences. Ther Drug Monit. 1998, 20:446-449.
120. Preskorn SH Clinically relevant pharmacology of selective serotonin reuptake inhibitors: An overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997, 32:1-21.
121. Preskorn SH Clinical Pharmacology of Selective Serotonin Inhibitors 1996, Professional Communications, Caddo, OK.
122. Klamerus KJ, Parker VD, Rudolph RL, et al. Effects of age and gender on venlafaxine and O-desmethylvenlafaxine pharmacokinetics. Pharmacotherapy. 1996, 16:915-923.
123. Ziegler VE, Biggs JT Tricyclic plasma levels: Effect of age, race, sex and smoking. JAMA 1977, 238:2167-2169.
124. Halbreich U, Asnis G, Ross D, Endicott J Amphetamine-induced dysphoria in postmenopausal women. Br J Psychiatry 1981, 138:470-473.
125. Hamilton JA, Alagna SW, Pinkel S Gender differences in antidepressant and activating drugs on self-perceptions. J Affective Disord 1984, 7:235-243.
126. Macgowan SH, Wilcock GK, Scott M Effect of gender and apolipo-protein E genotype in response to anticholinesterase therapy in Alzheimer's disease. Int J Geriatric Psychiatry 1998, 13:625-630.
127. Farlow MR, Lahiri DK, Poirer J, et al. Apolipoprotein E genotype and gender influence response to tacrine therapy. Ann New York Acad Sciences 1996, 802:101-110.
128. Chouinard G, Annable L Pimozide in the treatment of newly admitted schizophrenic patients. Psychopharmacology 1982, 76:13-19.
129. Szymanski S, Lieberman JA, Alvir JM, et al. Gender differences in onset of illness, treatment response, course, and biologic indexes in first-episode schizophrenic patients. Am J Psychiatry 1995, 152:698-703.
130. Kolakowska T, Williams AO, Ardern M, et al. Schizophrenia with good and poor outcome I. Early clinical features, response to neuroleptics and signs of organic dysfunction. Br J Psychiat 1985, 146:229-246.
131. Seeman MV Interaction of sex, age, and neuroleptic dose. Compr Psychiatry 1983, 24:219-236.
132. Melkersson KI, Hulting AL, Rane AJ Dose requirement and prolactin elevation of antipsychotics in male and female patients with schizophrenia or related psychoses. Br J Clin Pharmacology 2001, 51:317-324.
133. Chouinard G, Annable L, Steinberg S A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. J Clin Psychopharmacol 1986, 16:21-26.
134. D'Mello DA, MacNeil JA Sex differences in bipolar affective disorder: Neuroleptic dosage variance. Compr Psychiatry 1990, 31:80-83.
135. Simpson GM, Yadalam KG, Levinson DF, et al. Single dose pharmacokinetics of fluphenazine after fluphenazine decanoate administration. J Clin Psychopharmacol. 1990, 10:417-421.
136. Lane HY, Chang YC, Chang WH, et al. Effects of gender and age on plasma levels of clozapine and its metabolites: Analyzed by critical statistics. J Clin Psychiatry. 1999, 60:36-40.
137. Haring C, Fleischacker WW, Schett P, et al. Influence of patient-related variables on clozapine plasma levels. Am J Psychiatry. 1990, 147:1471-1475.
138. Fabrazzo M, Esposito G, Fusco R, et al. Effect of treatment duration on plasma levels of clozapine and N-desmethyl clozapine in men and women. Psychopharmacology 1996, 124:197-200.
139. Skogh E, Reis M, Dahl M, et al. Therapeutic drug monitoring data on olanzapine and its N-demethyl metabolite in the naturalistic clinical setting. Ther Drug Monit. 2002, 24:518-526.
140. Szymanski S, Lieberman JA, Pollack S, et al. Gender differences in neuroleptic nonresponsive clozapine-treated schizophrenics. Biol Psychiatry 1996, 39:249-254.
141. Pinals DA, Malhotra AK, Missar CD, et al. Lack of gender differences in neuroleptic response in patients with schizophrenia. Schizophr Res. 1996, 22:215-222.
142. Salonkangas RK Gender and the use of neuroleptics in schizophrenia. Further testing of the oestrogen hypothesis. Schizophr Res. 1995, 16:7-16.
143. Lindamer LA, Lohr JB, Harris MJ, Jeste DV Gender, estrogen, and schizophrenia. Psychopharmacol Bull. 1997, 33:221-228.
144. Majewska MD Sex differences in brain morphology and pharmacodynamics. Psychopharmacology and Women: Sex, Gender and Hormones 1996, 73-84. American Psychiatric Press, Washington, DC. M.F. Jensvold, U. Halbreich, J.A. Hamilton (Eds.).
145. Demyttenaere K, Enzlin P, Dewe W, et al. Compliance with antide-pressants in a primary care setting: The influence of gender and type of impairment. J Clin Psychiatry. 2001, 62:34-37.
146. Klein L, Klein M, Sturm H, et al. The frequency of adverse drug reactions as dependent upon age, sex and duration of hospitalization. Int J Clin Pharmacol. 1976, 13:187-195.
147. Rabkin J, Quitkin F, Harrison W, et al. Adverse reactions to monoamine oxidase inhibitors: Part I. a comparative study. J Clin Psychopharm. 1984, 4:270-278.
148. Isojarvi JL, Laatikainen TJ, Pakarinen AJ, et al. Polycystic ovaries and hyperandrogenism in women taking valproate for epilepsy. N Engl J Med 1993, 329:1383-1388.
149. McIntyre R, Mancini D, McCann S, et al. Valproate, bipolar disorder and polycystic ovarian syndrome. Bipolar Disord. 2003, 5:28-35.
150. Hammer MB, Arana GW Hyperprolactinemia in antipsychotictreated patients. CNS Drugs. 1998, 10:209-222.
151. Grunder G, Wetzel H, Schlosser R, et al. Neuroendocrine response to antipsychotics: Effects of drug type and gender. Biol Psychiatry. 1999, 45:89-97.
152. Amsterdam JD, Garcia-Espana F, Goodman D, et al. Breast enlargement during chronic antidepressant therapy. J Affect Disord. 1997, 46:151-156.
153. Charney DS, Goodman WK, Price CH, et al. Serotonin function in obsessive-compulsive disorder. A comparison of the effects of trytophan and m-chlorophenylpiperazine in patients and healthy subjects. Arch Gen Psychiatry. 1988, 65:177-185.
154. Mueller EA, Murphy DL, Sunderland T. Neuroendocrine effects of m-chlorophenylpiperazine, a serotonin agonist, in humans. J Clin Endocrinol Metab. 1985, 61:1179-1184.
155. Kleinberg DL, Davis JM, De Coster R, et al. Prolactin levels and adverse events in patients treated with risperidone. J Clin Psychopharmacol. 1999, 19:57-61.
156. Magharious W, Goff DC, Amico E Relationship of gender and menstrual status to symptoms and medication side effects in patients with schizophrenia. Psychiatry Res. 1998, 77:159-166.
157. Ackerman S, Nolan LJ Bodyweight gain induced by psychotropic drugs: Incidence, mechanisms and management. CNS Drugs. 1998, 9:135-151.
158. Pijl H, Meinders AE Bodyweight change as an adverse effect of drug treatment: Mechanism and management. Drug Safety. 1996, 14:329-342.
159. Martinez JA, Velasco JJ, Urbistondo MD Effects of pharmacological therapy on anthropometric and biochemical status of male and female institutionalized psychiatric patients. J Am Coll Nutr. 1994, 13:192-197.
160. Caro J, Ward A, Levinton C, Robinson K The risk of diabetes during olanzapine use compared with risperidone use: A retrospective database analysis. J Clin Psych. 2002, 63:1135-1139.
161. Koro CE, Fedder DO, L'Italien GJ, et al. Assessment of independent effect of olanzapine and risperidone on risk of diabetes among patients with schizophrenia: Population based nested case-control study. BMJ 2002, 325:243-248.
162. Koller EA, Doraiswamy PM Olanzapine-associated diabetes mellitus. Pharmacotherapy. 2002, 22:841-852.
163. Seeman MV, Lang M The role of estrogens in schizophrenia gender differences. Schizophr Bull. 1990, 16:185-194.
164. Keepers GA, Casey DE Prediction of neuroleptic-induced dystonia. J Clin Psychopharacol. 1987, 7:342-345.
165. Casey DE Neuroleptic drug-induced extrapyramidal symptoms and tardive dyskinesia. Schiz Research. 1991, 4:109-120.
166. Choinard G, Annable L, Ross-Choinard A, et al. Factors related to tardive dyskinesia. Am J Psychiatry. 1979, 136:79-83.
167. Smith JM, Kucharski LT, Oswald WT Tardive dyskinesia: Effect of age, sex, and criterion level of symptomatology on prevalence estimates. Psychopharmacol Bull. 1979, 15:69-71.
168. Yassa R, Jeste DV Gender differences in tardive dyskinesia: A critical review of the literature. Schizophrenia Bull. 1992, 18:701-715.
169. Smith JM, Dunn DD Sex differences in the prevalence of severe tardive dyskinesia. Am J Psychiatry. 1979, 136:1080-1082.
170. Morgenstern H, Glazer W Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medication. Arch Gen Psychiatry. 1993, 50:723-733.
171. Jeste DV, Lindameyer LA, Evans J, Lacro JP Relationship of ethnicity and gender to schizophrenia and pharmacology of neuroleptics. Psychopharmacology Bull. 1996, 32:243-251.
172. Welch R, Chue P Antipsychotics and QT changes. J Psychiatry Neuroscience. 2001, 25:154-160.
173. Auscher-Svanum H, Kennedy J, Stauffer VL, et al. Female Gender as a Risk Factor for Drug-Induced Cardiac Arrhythmia in Schizophrenia. Presented at the XIth Biennial Winter Workshop on Schizophrenia February 24-March 1, 2002.
174. Piscotta V Drug-induced agranulocytosis. Drug. 1978, 15:132-143.
175. Alvir JM, Lieberman JA Agranulocytosis: Incidence and risk factors. J Clin Psychiatry. 1994, 55:137-138.
176. Segraves RT Female sexual disorders: Psychiatric aspects. Can J Psychiatry 2002, 47:419-425.
177. Olfson M, Zarin DA, Mittman BS, McIntyre JS Is gender a factor in psychiatrists' evaluation and treatment of patients with major depression. J Affective Disorders. 2001, 63:149-157.
178. Piazza LA, Markowitz JC, Kocsis JH, et al. Sexual functioning in chronically depressed patients treated with SSRI antidepressants: A pilot study. Am J Psychiatry. 1997, 154:1757-1765.
179. Waldinger MD, Olivier B Sexual dysfunction and fluvoxamine therapy. J Clin Psychiatry. 2001, 62:126-127.
180. Shen WW, Hsu JH Female sexual side effects associated with selective serotonin reuptake inhibitors: A descriptive clinical study of 33 patients. Int J Psychiatry Med. 1995, 25:239-248.
181. Frazer A. Pharmacology of antidepressants. J Clin Psychopharmacology 1997, 17:2-18.
182. Boyarsky BK, Haque W, Rouleau MR, Hirschfeld RMA Sexual functioning in depressed outpatients taking mirtazapine. Depress Anxiety. 1999, 9:175-179.
183. Segraves RT, Croft H, Kavoussi R, et al. A placebo-controlled comparison of the antidepressant and sexual functioning of bupropion sustained release (SR) for the treatment of hypoactive sexual desire disorder (HSDD) in nondepressed women. J Sex Marital Ther. 2001, 27:303-316.
184. Landen M, Eriksson E, Agren H, Fahlen T Effect of buspirone on sexual dysfunction in depressed patients treated with selective serotonin reuptake inhibitors. J Clin Psychopharmacol. 1999, 19:268-271.
185. Zajecka J, Mitchell S, Fawsett J Treatment-emergent changes in sexual function with selective serotonin reuptake inhibitors as measured with the Rush Sexual Inventory. Psychopharmacol Bull. 1997, 33:755-760.
186. Nurnberg G, Lauriello J, Hensley P, et al. Sildenafil for iatrogenic serotonergic antidepressant medication-induced sexual dysfunction in four patients. J Clin Psychiatry. 1999, 60:33-35.
187. Smith SM, O'Keane V, Murray R Sexual dysfunction in patients taking conventional antipsychotic medication. Br J Psychiatry 2002, 181:49-55.
188. Compton MT, Miller AH Priapism associated with conventional and atypical antipsychotics: A review. J Clin Psychiatry. 2001, 62:362-366.
189. Aizenberg D, Modai I, Landa A, Gil-Ad I, et al. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin Psychiatry. 2001, 62:541-544.
190. Hummer M, Kemmler K, Kurz M, et al. Sexual disturbances during treatment with clozapine haloperidol treatment for schizophrenia. Am J Psychiatry. 1999, 156:631-633.
191. Aizenberg D, Sigler M, Zemishlany Z, Weizman A. Lithium and sexual male function in affective patients. Clin Neuropharmacol. 1999, 19:515-519.
192. Isojarvi J, Repo M, Pakarinen A, et al. Carbamazepine, phenytoin, sex hormones, and sexual function in men with epilepsy. Epilepsia 1995, 36:366-370.
193. Segraves RT The effects of minor tranquilizers, mood stabilizers and antipsychotics on sexual function. Primary Psychiatry. 1999, 6:37-40.